These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12225332)

  • 1. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
    J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
    Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
    Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Hisanaga Y
    Cancer; 2000 Jan; 88(1):58-65. PubMed ID: 10618606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
    Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
    Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
    Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
    Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Takayanagi M; Yoshioka K; Kakumu S; Iijima A; Urushihara A; Kiyosawa K; Okuda M; Hino K; Okita K
    Hepatology; 1998 May; 27(5):1394-402. PubMed ID: 9581697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
    Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hayashi N; Kasahara A
    Oncology; 2002; 62 Suppl 1():87-93. PubMed ID: 11868793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
    Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
    J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C.
    Miyake Y; Iwasaki Y; Yamamoto K
    Int J Cancer; 2010 Aug; 127(4):989-96. PubMed ID: 19957327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.
    Hino K; Okita K
    J Antimicrob Chemother; 2004 Jan; 53(1):19-22. PubMed ID: 14657083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
    Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.